

Curriculum Vitae

INFORMAZIONI PERSONALI

Nome MANFREDI
Cognome RIZZO
Recapiti Dipartimento Biomedico di Medicina Interna e Specialistica
Telefono 091-6552945
E-mail manfredi.rizzo@unipa.it

FORMAZIONE TITOLI

ATTIVITA' DIDATTICA

ATTIVITÀ DIDATTICA

Corsi di Laurea magistrale a ciclo unico

2005-2009 Docente di "Medicina Interna" del corso integrato di "Medicina Interna" del corso di laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell' Università di Palermo (polo didattico di Caltanissetta).

2010-2012 Docente di "Medicina Interna" del corso di recupero per studenti fuori corso del corso di laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell' Università di Palermo (polo didattico di Palermo).

2009-2013 Docente del corso monografico ADO (attività didattica integrativa) "Ecografia Vascolare" del corso di laurea in Medicina e Chirurgia della Facoltà di Medicina e Chirurgia dell' Università di Palermo

Corsi di Laurea

2005-2009 Docente di "Medicina Interna" del corso integrato di "Medicina Interna, Chirurgia Generale, Farmacologia e Infermieristica Clinica Applicata" del corso di laurea in Infermieristica della Facoltà di Medicina e Chirurgia dell' Università di Palermo (polo didattico di Trapani).

2007-2009 Docente di "Scienze tecniche dietetiche applicate" del corso integrato di "Igiene generale, Medicina del Lavoro, Medicina Preventiva e di comunità" del corso di laurea in Infermieristica della Facoltà di Medicina e Chirurgia dell' Università di Palermo (polo didattico di Palermo, ARNAS Civico).

2009-2010 Docente di "Medicina Interna" del corso integrato di "Scienze medico-chirurgiche" del corso di laurea in Igiene Dentale della Facoltà di Medicina e Chirurgia dell' Università di Palermo.

2009-2010 Docente di "Malattie dell' apparato cardiovascolare" del corso integrato di "Medicina specialistica I" del corso di laurea in Infermieristica della Facoltà di Medicina e Chirurgia dell' Università di

Palermo (polo didattico di Agrigento).

2009-2011 Docente di "Medicina Interna" del corso integrato di "Primo Soccorso" del corso di laurea in Igiene Dentale della Facoltà di Medicina e Chirurgia dell' Università di Palermo.

2011-2012 Docente di "Prevenzione e Nutrizione Clinica" del corso integrato di "Fisiologia della Nutrizione e Prevenzione e Nutrizione Clinica" del corso di laurea Interfacoltà in Biologia della Salute dell' Università di Palermo.

2012-2013 Docente di "Medicina Interna" del corso integrato di "Medicina Interna e Diagnostica per Immagini" del corso di laurea in Tecniche di Laboratorio Biomedico dell' Università di Palermo.

Corsi di Specializzazione

2005-2007 Docente di "Semeiotica Cardio-Angiologica" del V anno della Scuola di Specializzazione in Medicina Interna I dell' Università di Palermo.

2009-2011 Docente di "Medicina Interna" del I anno della Scuola di Specializzazione in Cardiologia dell' Università di Palermo.

Corsi di Dottorato di Ricerca

2007-2011 Docente del Dottorato di Ricerca "Fisiopatologia del Metabolismo: Lipidi e Lipoproteine" dell' Università di Palermo.

2011-2013 Docente del Dottorato di Ricerca "Biomedicina e Neuroscienze" indirizzo "Medicina Sperimentale e Molecolare" dell' Università di Palermo.

RICERCHE FINANZIATE

- *PRIN (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale)*

2006-2007: "Studio genetico-biochimico delle relazioni tra il metabolismo dei prostanoidi e la ipoalfalipoproteinemia" (protocollo 2006063532002)

- *PROGETTI DI RICERCA DI ATENEIO (ex 60%)*

2008 (anno finanziario 2007): "Ruolo della dislipidemia aterogena nella sindrome metabolica e relazione con l'aterosclerosi subclinica e clinica" (codice ORPA074793)

2007 (anno finanziario 2006): "Studio genetico-biochimico delle relazioni tra il metabolismo dei prostanoidi e la ipoalfalipoproteinemia" (codice ORPA06AX3M)

"Prevalenza della sindrome metabolica in una comunità isolata: Lo Studio di Ustica" (codice ORPA06RYMB)

2006 (anno finanziario 2005): "Studio clinico-genetico della sindrome chilomicronemica" (codice ORPA055457)

2005 (anno finanziario 2004): "Studio genetico-biochimico delle relazioni tra il metabolismo dei prostanoidi e le dislipidemie genetiche" (codice ORPA042083)

INCARICHI / CONSULENZE

MEMBRO DELL'EDITORIAL BOARD DELLE SEGUENTI RIVISTE SCIENTIFICHE INTERNAZIONALI:

1. Lipid Insights (2008-)
2. The Open Atherosclerosis & Thrombosis Journal (2008-)
3. World Journal of Cardiology (2009-)
4. Journal of Drug Assessment (2010-)
5. World Journal of Diabetes (2010-)
6. Clinical Medicine Insights: Endocrinology and Diabetes (2011-)
7. Angiology (2011-) [**con Impact Factor 2011 di 1,511**]
8. Hospital Chronicles (2012-)
9. Archives of Medical Science, Section Editor in Metabolic Disorders (2012-) [**con Impact Factor 2011 di 1,214**]
10. Current Vascular Pharmacology (2012-) [**con Impact Factor 2011 di 2,869**]
11. Current Drug Therapy, (2013-)
12. Cardiovascular Continuum, Deputy Editor in Chief (2013-)
13. Biochemical Compounds, Senior Editor (2013-)
14. Clinical Lipidology (2013-) [**con Impact Factor 2011 di 0,754**]

ASSOCIAZIONI SCIENTIFICHE

SOCIETA' SCIENTIFICHE DI APPARTENENZA

1. International Atherosclerosis Society (IAS)
2. European Atherosclerosis Society (EAS)
3. Royal Society for Public Health (RSPH)
4. Societa' Italiana di Diabetologia (SID)
5. Societa' Italiana di Medicina Interna (SIMI)

PUBBLICAZIONE

IN EXTENSO

IN RIVISTE INTERNAZIONALI CON IMPACT FACTOR (JOURNAL OF CITATION REPORTS)

1. Barbagallo CM, Fan J, Blanche PJ, **Rizzo M**, Taylor JM, Krauss RM. Overexpression of human hepatic lipase and apoE in transgenic rabbits attenuates response to dietary cholesterol and alters lipoprotein subclass distributions. *Arterioscler Thromb Vasc Biol* 1999; 19:625-632.
1. Barbagallo CM, Cefalù AB, Gallo S, **Rizzo M**, Noto D, Cavera G, Rao Camemi A, Marino G, Caldarella R, Notarbartolo A, Averna MR. Effects of mediterranean diet on lipid levels and cardiovascular risk in renal transplant recipients. *Nephron* 1999; 82:199-204.
1. Tribble DL, **Rizzo M**, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. *Am J Med* 2001; 110:103-110.
1. Barbagallo CM, Polizzi F, Severino M, **Rizzo M**, Vivona N, Onorato F, Caldarella R, Cefalù AB, Noto D, Notarbartolo A, Averna MR. ApoE polymorphism in a small mediterranean island: relationships with plasma lipids, lipoproteins and LDL particle size. *Eur J Epidemiol* 2001; 17:707-13.
1. Barbagallo CM, **Rizzo M**, Cefalù AB, Noto D, Scimeca A, Castello A, Sarullo F, Notarbartolo A, Averna MR. Changes in plasma lipids and low-density lipoprotein peak particle size during and after myocardial infarction. *Am J Cardiol* 2002; 89:460-2.

1. Barbagallo CM, Cavera G, Sapienza M, Noto D, Cefalù AB, Polizzi F, Onorato F, Rini GB, Di Fede G, Pagano M, Montalto G, **Rizzo M**, Descovich GC, Notarbartolo A, Averna MR. Nutritional characteristics of a rural southern Italy population: the Ventimiglia di Sicilia project. *J Am Coll Nutr* 2002; 21:523-9.
1. Barbagallo CM, Polizzi F, Severino M, Onorato F, Noto D, Cefalù AB, **Rizzo M**, Notarbartolo A, Averna MR. Distribution of risk factors, plasma lipids, lipoproteins and dyslipidemias in a small mediterranean island: the Ustica project. *Nutr Metab Cardiovasc Dis* 2002; 12:267-274.
1. Barbagallo CM, Emmanuele G, Cefalu' AB, Fiore B, Noto D, Mazzarino MC, Pace A, Brogna A, **Rizzo M**, Corsini A, Notarbartolo A, Travali S, Averna MR. Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. *Atherosclerosis* 2003; 166:395-400.
1. Noto D, Pace A, Cefalu' AB, Barbagallo CM, **Rizzo M**, Marino G, Emmanuele G, Travali S, Notarbartolo A, Averna M. Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. *Clin Chim Acta* 2003; 328:91-97.
1. **Rizzo M**, Barbagallo CM, Severino M, Polizzi F, Onorato F, Noto D, Cefalù AB, Pace A, G Marino, Notarbartolo A, Averna RM. Low-density-lipoprotein peak particle size in a Mediterranean population. *Eur J Clin Invest* 2003; 33:126-133.
1. Mansueto P, **Rizzo M**, Affronti M, Malta R, Carmina E, Mansueto S, Masellis M, Rini GB. Safe and successful endoarterial infusion of liposomal amphotericin B in treatment of mucormycosis. *Microbiologica* 2003; 26:395-398.
1. **Rizzo M**, Mansueto P, Di Lorenzo G, Morselli S, Mansueto S, Rini GB. Rickettsial disease: classical and modern aspects. *Microbiologica* 2004; 27:87-103.
1. **Rizzo M**, Taylor JM, Barbagallo CM, Berneis KK, Blanche PJ, Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. *Arterioscler Thromb Vasc Biol* 2004; 24:141-146.
1. Berneis KK, Shames DM, Blanche PJ, La Belle M, **Rizzo M**, Krauss RM. Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. *Metabolism* 2004; 53:483-7.
1. Barbagallo CM, Averna MR, Citarrella R, **Rizzo M**, Amato M, Noto D, Pugliese A, Cefalù AB, Galluzzo A, Giordano C. Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. *Eur J Endocrinol* 2004; 150:831-6.
1. Berneis K, **Rizzo M**. LDL size: does it matter ? *Swiss Med Wkly* 2004; 134:720-724.
1. **Rizzo M**, Di Fede G, Mansueto P, Castello F, Carmina E, Rini GB. Statins and osteoporosis: myth or reality ? *Minerva Medica* 2004; 95:521-7.

1. Noto D, Cefalu' AB, Barbagallo CM, Pace A, **Rizzo M**, Marino G, Caldarella R, Castello A, Pernice V, Notarbartolo A, Averna MR. Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels. *Int J Cardiol* 2005; 101:213-217.
1. Superko RH, Berneis KK, Williams P, **Rizzo M**, Wood P. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. *Am J Cardiol* 2005; 96:1266-72.
1. **Rizzo M**, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention ?. *J Atheroscler Thromb* 2005; 12:237-9.
1. **Rizzo M**, Barbagallo CM, Noto D, Pace A, Cefalu' AB, Pernice V, Pinto V, Rubino A, Pieri D, Traina M, Frasheri A, Notarbartolo A, Averna MR. Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study. *Nutr Metab Cardiovas Dis* 2005; 15:361-7.
1. **Rizzo M**, Mansueto P, Cabibi D, Barresi E, Berneis K, Affronti M, Di Lorenzo G, Vigneri S, Rini GB. A case of bowel schistosomiasis that did not adhere to the endoscopic findings. *World J Gastroenterol* 2005; 11:7044-47.
1. **Rizzo M**, Berneis K. Low-density-lipoproteins size and cardiovascular prevention. *Eur J Intern Med* 2006; 17:77-80.
1. **Rizzo M**, Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment *QJM* 2006; 99:1-14.
1. **Rizzo M**, Berneis K. Should we measure routinely the LDL peak particle size ? *Int J Cardiol* 2006; 107:166-170.
1. Corrado E, **Rizzo M**, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5 years follow-up study. *Stroke* 2006; 37:482-6
1. **Rizzo M**, Berneis K, Corrado E, Novo S. The significance of low-density lipoproteins size in vascular diseases. *Int Angiol* 2006; 25:4-9.
1. Carmina E, Rosato F, Janni A, **Rizzo M**, Longo RA. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab* 2006; 91:2-6.
1. Barbagallo CM, **Rizzo M**, Noto D, Frasheri A, Pernice V, Rubino A, Pieri D, Pinto V, Cefalù AB, Giordano C, Notarbartolo A, Averna MR. Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. *Metabolism* 2006; 55:662-8.
1. **Rizzo M**, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. *Cardiovasc Drugs Ther* 2006; 20:205-217.
1. **Rizzo M**, Rini GB. Statins, fracture risk and bone remodeling: what is true? *Am J Med Sci* 2006; 332:55-60.

1. Noto D, **Rizzo M**, Barbagallo CM, Cefalu' AB, Lo Verde A, Fayer F, Notarbartolo A, Averna MR. Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. *Metabolism* 2006; 55:1308-1316.
1. **Rizzo M**, Berneis K. Effects of statins on low-density-lipoproteins size: a new role in cardiovascular prevention ? *South Med J* 2006; 99:1015-16.
1. Corrado E, **Rizzo M**, Muratori I, Coppola G, Novo S. Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type-II diabetes. *Arch Med Res* 2006; 37:1004-1009
1. **Rizzo M**, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. *Diabetes Metab Res Rev* 2007; 23:14-20.
1. Berneis K, **Rizzo M**, Fruzzetti F, Lazzarini V, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2007; 92:186-189.
1. **Rizzo M**, Migneco A, Mansueto P, Tringali G, Di Lorenzo G, Rini GB. The therapeutic patient education in oncology: pedagogical notions for women's health and prevention. *Eur J Cancer Care* 2007; 16:9-11.
1. **Rizzo M**, Trepp R, Berneis K, Christ ER. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. *Eur J Endocrinol* 2007; 156:361-7.
1. **Rizzo M**, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. *Curr Med Res Opin* 2007; 23:1103-1111.
1. **Rizzo M**, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. *Adv Ther* 2007; 24:575-82.
1. **Rizzo M**, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. *Exp Clin Endocrinol Diabetes* 2007; 115:477-82.
1. **Rizzo M**, Berneis K. Who needs to care about small, dense low density lipoproteins? *Int J Clin Pract* 2007; 61:1949-56.
1. Campolo L, Pantaleo P, Barattoni MC, Berardo A, Ghetti L, Fusco D, Cremonesi A, Gattoni C, Marchese A, Pernice V, Alberti A, Gliozheni E, Perucci C on behalf of the Restem Investigators (incluso **Rizzo M**). RESTEM: A Percutaneous Coronary Intervention "real world" Registry in the drug-eluting stent era. *Coron Artery Dis* 2007; 18:653-62.
1. Noto D, Cottone S, Cefalù AB, Vadalà A, Barbagallo CM, **Rizzo M**, Pernice V, Minà M, Fayer F, Cerasola G, Notarbartolo A, Averna MR. Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. *Thromb Haemost* 2007; 98:1362-7.

1. **Rizzo M**, Rini GB, Carmina E. Androgen excess and cardiovascular risk. *Minerva Endocrinol* 2007; 32:67-71.

1. **Rizzo M**, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome ? *Am J Obstet Gynecol* 2008; 198:28.e1-5.

1. Berneis K, **Rizzo M**, Stettler C, Chappuis B, Braun M, Diem P, Christ ER. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type-2 diabetes. *Expert Opin Pharmacother* 2008; 9:343-49

1. **Rizzo M**, Corrado E, Coppola G, Muratori I, Novo S. Prediction of cerebrovascular and cardiovascular events in patients with subclinical carotid atherosclerosis: the role of C-reactive protein. *J Investig Med* 2008; 56:32-40.

1. **Rizzo M**, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. *Atherosclerosis* 2008; 197:237-241.

1. Corrado E, **Rizzo M**, Muratori I, Coppola G, Novo S. Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions. *Menopause* 2008; 15:240-247.

1. **Rizzo M**, Berneis K. Do we need better lipid tools for cardiovascular risk assessment ? *South Med J* 2008; 101:221.

1. **Rizzo M**, Trepp R, Berneis K, Christ ER. Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. *Growth Horm IGF Res* 2008; 18:264-266.

1. Corrado E, **Rizzo M**, Coppola G, Muratori I, Carella M, Novo S. Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study. *Coron Artery Dis* 2008; 19:139-144.

1. **Rizzo M**, Christ ER, Rini GB, Spinass GA, Berneis K. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type-2 diabetes: what is the clinical significance ? *Expert Opin Pharmacother* 2008; 9:2295-303.

1. **Rizzo M**, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. *Atherosclerosis* 2008; 200:389-395.

1. **Rizzo M**, Berneis K, Altinova AE, Toruner FB, Akturk M, Ayvaz G, Rini GB, Spinass GA, Arslan M. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. *Diabet Med* 2008;25:1406-11.

1. **Rizzo M**, Berneis K. Recent insights on dark chocolate consumption and cardiovascular risk. *South Med J* 2008; 101:1194.

1. **Rizzo M**, Rini GB, Spinus G, Berneis K. A practical method to determine the "atherogenic lipoprotein phenotype". *Arch Med Sci* 2008; 4:215-218.
1. Mansueto P, Di Lorenzo G, **Rizzo M**, Di Rosa S, Vitale G, Rini GB, Mansueto S, Affronti M. Fever of unknown origin in a mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991-2002). *Intern Emerg Med* 2008; 3:219-25.
1. **Rizzo M**, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. *Coron Artery Dis* 2009; 20:15-20.
1. Berneis K, **Rizzo M**, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinus GA, Carmina E. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. *Int J Clin Pract* 2009; 63:56-62.
1. **Rizzo M**, Berneis K, Spinus GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ? *Int J Clin Pract* 2009; 63: 478-485.
1. **Rizzo M**, Rizvi AA, Rini GB, Berneis K. The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? *Acta Diabetol* 2009; 46: 1-11.
1. **Rizzo M**, Berneis K, Spinus GA, Rini GB, Carmina E. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. *Fertil Steril* 2009; 91(4 Suppl):1563-7.
1. **Rizzo M**, Kotur-Stevuljevic J, Berneis K, Spinus GA, Rini GB, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. *Transl Res* 2009; 153: 217-223.
1. **Rizzo M**, Pernice V, Frasheri A, Di Lorenzo G, Rini GB, Spinus GA, Berneis K. Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. *Clin Endocrinol* 2009; 70: 870-875.
1. **Rizzo M**, Krayenbühl PA, Pernice V, Frasheri A, Rini GB, Berneis K. LDL size and subclasses in patients with abdominal aortic aneurysm. *Int J Cardiol* 2009; 134: 406-408.
1. **Rizzo M**, Rini GB, Spinus GA, Berneis K. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ? *Atherosclerosis* 2009; 204: 330-333.
1. Di Lorenzo G, Mansueto P, Pacor ML, **Rizzo M**, Castello F, Martinelli N, Ditta V, Lo Bianco C, Leto-Barone MS, D'Alcamo A, Di Fede G, Rini GB, Ditto AM. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. *J Allergy Clin Immunol* 2009; 123: 1103-10.
1. Tkacova R, **Rizzo M**, Berneis K. Therapy with non-invasive ventilation in patients with obstructive sleep apnoea: effects on atherogenic lipoprotein phenotype. *Med Hypotheses* 2009; 73: 441-4.

1. Berneis K, **Rizzo M**, Spinass GA, Di Lorenzo G, Di Fede G, Pepe I, Pernice V, Rini GB. The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. *Clin Chim Acta* 2009; 406: 36-40.
1. **Rizzo M**, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinass GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory vs. anovulatory polycystic ovary syndrome phenotype. *Hum Reprod* 2009; 24: 2286-2292.
1. **Rizzo M**, Rizvi AA, Spinass GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors. *Expert Opin Investig Drugs* 2009; 18: 1495-1503.
1. **Rizzo M**, Corrado E, Coppola G, Muratori I, Mezzani A, Novo G, Novo S. The predictive role of C-reactive protein in subjects with hypertension and subclinical atherosclerosis. *Intern Med J* 2009; 39: 539-45.
1. **Rizzo M**, Spinass GA, Cesur M, Ozbalkan Z, Rini GB, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. *Atherosclerosis* 2009; 207: 502-506.
1. Di Lorenzo G, Mansueto P, Pacor ML, Martinelli N, **Rizzo M**, Ditta V, Leto-Barone MS, D'Alcamo A, Politi D, Pepe I, Rotolo G, Di Fede G, Caruso C, Rini GB, Corrocher R. Clinical importance of eosinophil count in nasal fluid in patients with allergic and non-allergic rhinitis. *Int J Immunopathol Pharmacol* 2009; 22:1077-1087.
1. **Rizzo M**, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? *Clin Lab* 2009; 55:421-429.
1. Berneis K, **Rizzo M**, Evans J, Rini GB, Spinass GA, Goedecke JH. Interleukin-18 levels are associated with low-density lipoproteins size. *Eur J Clin Invest* 2010; 40:54-55.
1. Corrado E, **Rizzo M**, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. *J Atheroscler Thromb* 2010; 17:1-11.
1. **Rizzo M**. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. *IDrugs* 2010; 13:103-11.
1. Berneis K, **Rizzo M**, Berthold HK, Spinass GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small, dense low-density lipoproteins in healthy men: a randomized trial. *Eur Heart J* 2010; 31:1633-1639.
1. Goedecke JH, Utschneider K, Faulenbach MV, **Rizzo M**, Berneis K, Spinass GA, Dave J, Levitt NS, Lambert EV, Olsson T, Kahn SE. Ethnic differences in serum lipoproteins and their determinants in south african women. *Metabolism* 2010; 59: 1341-1350.
1. **Rizzo M**, Vekic J, Koulouris S, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Rini GB, Sakellariou D, Pastromas S, Mikhailidis DP, Manolis AS. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type-2 diabetes. *Angiology* 2010; 61:584-90.

1. **Rizzo M**, Spinas GA, Rini GB, Berneis K. Is diabetes the cost to pay for a greater cardiovascular prevention ? *Int J Cardiol* 2010; 144:309-310.
1. Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K, **Rizzo M**. An update on the relationships between rheumatoid arthritis and atherosclerosis. *Atherosclerosis* 2010; 212:377-382.
1. **Rizzo M**, Berneis K, Koulouris S, Pastromas S, Rini GB, Sakellariou D, Manolis AS. Should we measure routinely oxidized and small dense low-density lipoproteins in subjects with type 2 diabetes? *Int J Clin Pract* 2010; 64:1632-42.
1. **Rizzo M**, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? *Expert Opin Pharmacother*. 2011;12:647-55.
1. Wild RA, **Rizzo M**, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. *Fertil Steril*. 2011; 95:1073-1079.e11.
1. **Rizzo M**, Rini GB. Ezetimibe, cardiovascular risk and atherogenic dyslipidemia. *Arch Med Sci* 2011; 7: 5-7.
1. Novo G, Cappello F, **Rizzo M**, Fazio G, Zambuto S, Tortorici E, Gammazza AM, Corrao S, Zummo G, de Macario EC, Macario AJ, Assennato P, Novo S, Volti GL. Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. *Transl Res* 2011; 157:285-92.
1. **Rizzo M**, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. *Curr Pharm Des*. 2011;17:943-949.
1. Mikhailidis DP, Elisaf MS, **Rizzo M**, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos EN. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. *Curr Vasc Pharmacol* 2011; 9:533-571.
1. Mikhailidis DP, Elisaf MS, **Rizzo M**, Berneis K, Griffin B, Zambon A, Athyros V, de Graaf J, März W, Parhofer KG, Rini GB, Spinas GA, Tomkin GH, Tselepis AD, Wierzbicki AS, Winkler K, Florentin M, Liberopoulos EN. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. *Curr Vasc Pharmacol* 2011; 9:531-2.
1. **Rizzo M**, Longo RA, Guastella E, Rini GB, Carmina E. Assessing cardiovascular risk in mediterranean women with polycystic ovary syndrome. *J Endocrinol Invest* 2011; 34:422-6.
1. **Rizzo M**, Tomkin GH, Patti AM, Pepe I, Valerio MR, Di Rosa S, Rini GB, Di Fede G. Effects of hypolipidemic and hypoglycaemic agents on atherogenic small, dense low-density lipoproteins in type-2 diabetes. *Clin Lipidol* 2011; 6:539-547.

1. **Rizzo M**, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. *Curr Pharm Des* 2011; 17:3608-3610.
1. Haidara M, Mikhailidis DP, Yassin HZ, Soskic S, Dobutovic B, Mousa S, **Rizzo M**, Isenovic ER. Evaluation of the possible contribution of administration of antioxidants on metabolic syndrome. *Curr Pharm Des* 2011; 17:3699-3712.
1. Tselepis AD, **Rizzo M**, Goudevenos IA. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). *Curr Pharm Des* 2011; 17:3656-3661.
1. **Rizzo M**, Macario AJL, de Macario EC, Gouni-Berthold I, Berthold HK, Rini GB, Zummo G, Cappello F. Heat shock protein-60 and cardiovascular risk. *Curr Pharm Des* 2011; 17:3662-3668.
1. Tomasello G, Rodolico V, Zerilli M, Martorana A, Bucchieri F, Pitruzzella A, Gammazza AM, David S, Rappa F, Zummo G, Damiani P, Accomando S, **Rizzo M**, de Macario EC, Macario AJ, Cappello F. Changes in Immunohistochemical Levels and Subcellular Localization After Therapy and Correlation and Colocalization With CD68 Suggest a Pathogenetic Role of Hsp60 in Ulcerative Colitis. *Appl Immunohistochem Mol Morphol* 2011; 19:552-561.
1. Purnak T, Efe C, Beyazit Y, Ozaslan E, Astan R, Milanlioglu A, Özbalkan Z, **Rizzo M**. Recent insights into the relationships between inflammatory liver diseases and atherosclerosis. *J Investig Med* 2011;59:904-11.
1. **Rizzo M**, Mikhailidis DP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. *Clin Endocrinol (Oxf)*. 2012; 76:177-178.
1. Novo G, **Rizzo M**, Carruba SL, Caruso M, Amoroso GR, Balistreri CR, Coppola G, Evola G, Caruso C, Assennato P, Novo S, Mancuso D. The role of macrophage colony-stimulating factor in patients with acute myocardial infarction: a pilot study. *Angiology* 2012 Feb;63(2):127-30.
1. Corrado E, Bacarella D, Coppola G, **Rizzo M**, Murotori I, Dell'Oglio S, Nugara C, Ferrara F, Novo S. Medical therapy for patients with subclinical and clinical carotid atherosclerosis. *Int Angiol* 2012;31:1-9.
1. **Rizzo M**, Montalto G, Banach M. The effects of statins on blood pressure: current knowledge and future perspectives. *Arch Med Sci* 2012;8:1-3.
1. **Rizzo M**, Cappello F, Marfil R, Nibali L, Marino Gammazza A, Rappa F, Bonaventura G, Galindo-Moreno P, O'Valle F, Zummo G, Conway de Macario E, Macario AJ, Mesa F. Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study. *Cell Stress Chaperones*. 2012;17:399-407.
1. D'Anna SE, Asnaghi R, Caramori G, Appendini L, **Rizzo M**, Cavallaro C, Marino G, Cappello F, Balbi B, Di Stefano A. High-Resolution Computed Tomography Quantitation of Emphysema Is Correlated with Selected Lung Function Values in Stable COPD. *Respiration* 2012;83:383-90.
1. Corrado E, **Rizzo M**, Aluigi L, Patti AM, Coppola G, Murotori I, Caccamo G, Balasus F, Novo S. Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome; the role of markers of inflammation. *Int Angiol* 2012;31:219-26.

1. **Rizzo M**, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. *Arch Med Sci* 2012;8:598-600.
1. Gouni-Berthold I, Mikhailidis DP, **Rizzo M**. Clinical benefits of ezetimibe use: is absence of proof, proof of absence? *Expert Opin Pharmacother* 2012;13:1985-1988.
1. **Rizzo M**, Montalto G, Rizvi AA, Christ ER. The role of elevated growth hormone on the increased atherosclerosis in patients with acromegaly. *Angiology* 2012;63:492-494.
1. Sopkova Z, Berneis K, **Rizzo M**, Spinass GA, Dorkova Z, Tisko R, Tkacova R. Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea. *Angiology* 2012;63:617-621.
1. Corrado E, **Rizzo M**, Caccamo G, Coppola G, Muratori I, Tantillo R, Dell'oglio S, Nugara C, Macaione F, Novo G, Alcamo R, Mignano A, Ferrara F, Novo S. Prevalence of metabolic syndrome: a comparative analysis in an unselected sample of mediterranean subjects. *Int Angiol* 2012;31:572-8.
1. Nibali L, Tatarakis N, Needleman I, Tu YK, D'Aiuto F, **Rizzo M**, Donos N. Association between metabolic syndrome and periodontitis: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2013;98:913-20.
1. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, **Rizzo M**. Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. *Nutrients* 2013;5:928-948.
1. **Rizzo M**, Nikolic D, Banach M, Giglio RV, Patti AM, Di Bartolo V, Tamburello A, Zabbara A, Pecoraro G, Montalto G, Rizvi AA. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. *Clin Lipidol* 2013;8:173-181.
1. Bielecka-Dabrowa A, Mikhailidis DP, **Rizzo M**, von Haehling S, Rysz J, Banach M. The influence of atorvastatin on parameters of inflammation, left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy - 5-year follow-up. *Lipids Health Dis* 2013;12:47.
1. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, **Rizzo M**, Rysz J, Abdollahi M, Nicholls SJ, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants. *Pharmacol Res* 2013;72:35-44.
1. Nikolic D, Nikfar S, Salari P, **Rizzo M**, Ray KK, Pencina MJ, Mikhailidis DP, Toth PP, Nicholls SJ, Rysz J, Abdollahi M, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. *Curr Med Res Opin* 2013;29:435-51.
1. Banach M, **Rizzo M**, Obradović M, Montalto G, Rysz J, Mikhailidis DP, Isenović ER. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders? *Curr Pharm Des* 2013;19:3869-3877.

1. **Rizzo M**, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined Dyslipidemia: Should The Focus Be LDL Cholesterol or Atherogenic Dyslipidemia? *Curr Pharm Des* 2013;19:3858-3868.
1. Barkas F, **Rizzo M**, DiNicolantonio JJ, Liberopoulos E. Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope? *Clin Lipidol* 2013;8:273-277.
1. Gouni-Berthold I, **Rizzo M**, Berthold HK. Mipomersen: A lipid-lowering agent with a novel mechanism of action. *Clin Lipidol* 2013;8:279-282.
1. Kei A, Liberopoulos E, Tellis K, **Rizzo M**, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidaemia: a randomized pilot trial. *Eur J Clin Invest* 2013; 43:698–707.
1. Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, **Rizzo M**. The Role of Fibrate Treatment in Dyslipidemia: An Overview. *Curr Pharm Des* 2013;19:3124-31.
1. **Rizzo M**, Avogaro A, Montalto G, Rizvi AA. Non-glycemic effects of pioglitazone and incretin-based therapies. *Expert Opin Ther Targets* 2013;17:739-42.
1. Gouni-Berthold I, **Rizzo M**. Can statins mitigate the adverse cardiovascular effects of smoking? *Curr Vasc Pharmacol*. 2012 Dec 18. [Epub ahead of print]
1. Stepien M, Stepien A, Wlazel RN, Paradowski M, **Rizzo M**, Banach M, Rysz J. Predictors of insulin resistance in patients with obesity: a pilot study. *Angiology*. 2012 Dec 23. [Epub ahead of print]
1. **Rizzo M**, Rizvi AA, Sudar E, Soskic S, Obradovic M, Montalto G, Boutjdir M, Mikhailidis DP, Isenovic ER. A Review of the Cardiovascular and Anti-atherogenic Effects of Ghrelin. *Curr Pharm Des*. 2012 Dec 26. [Epub ahead of print]
1. **Rizzo M**, Montalto G, Vinciguerra M. Exploring lipid-related treatment options for the treatment of NASH. *Curr Vasc Pharmacol*. 2012 Dec 28. [Epub ahead of print]
1. **Rizzo M**, Sopkova Z, Patti AM, Tkacova R. Smoking and small, dense low-density lipoproteins. *Angiology*. 2013 Mar 20. [Epub ahead of print]
1. **Rizzo M**, Obradovic M, Labudovic-Borovic M, Nikolic D, Montalto G, Rizvi AA, Mikhailidis DP, Isenovic ER. Uric acid metabolism in prehypertension and the metabolic syndrome. *Curr Vasc Pharmacol* 2013 Apr 25. [Epub ahead of print]
1. Stepien M, Stepien A, Banach M, Wlazel RN, Paradowski M, **Rizzo M**, Toth PP, Rysz J. New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension: Comparative Pilot Analysis. *Angiology*. 2013 May 1. [Epub ahead of print]

1. Resanovic I, **Rizzo M**, Zafirovic S, Bjelogrljic P, Perovic M, Savic K, Patti AM, Isenovic RE. Anti-atherogenic Effects of 17-Estradiol. *Horm Metab Res*. 2013 May 16. [Epub ahead of print]

1. Mosiewicz J, Pietrzak A, Chodorowska G, Trojnar M, Szepietowski J, Reich K, **Rizzo M**. Rational for statin use in psoriatic patients. *Arch Dermatol Res*. 2013 Jun 11. [Epub ahead of print]

1. **Rizzo M**, Giglio RV, Nikolic D, Patti AM, Campanella C, Cocchi M, Katsiki N, Montalto G. Effects of Chitosan on Plasma Lipids and Lipoproteins: A 4-Month Prospective Pilot Study. *Angiology*. 2013 Jun 18. [Epub ahead of print]

1. Obradovic MM, Bjelogrljic P, **Rizzo M**, Katsiki N, Haidara M, Stewart AJ, Jovanovic A, Isenovic ER. Effects of obesity and estradiol on Na⁺/K⁺-ATPase and their relevance to cardiovascular disease. *J Endocrinol*. 2013 Jun 19. [Epub ahead of print]

1. Mirjanic-Azaric B, **Rizzo M**, Sormaz L, Stojanovic D, Uletilovic S, Sodin-Semrl S, Lakota K, Artenjak A, Marc J, Cerne D. Atorvastatin in stable angina patients (20 mg/day, 10 weeks) lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. *Clin Biochem*

ATTIVITA' SCIENTIFICHE

ATTIVITA' DI REVIEWER PER RIVISTE SCIENTIFICHE INTERNAZIONALI CON IMPACT FACTOR

1. Acta Paediatrica (2009)
2. Aging Research Reviews (2011)
3. Angiology (2011)
4. Annals of Nutrition and Metabolism (2007)
5. Annals of Family Medicine (2007, 2009)
6. Archives of Medical Research (2007)
7. Archives of Medical Science (2012, 2013)
8. Archives of Oral Biology (2012)
9. Arteriosclerosis, Thrombosis and Vascular Biology (2008)
10. Atherosclerosis (2007, 2008, 2009, 2010, 2011, 2012, 2013)
11. BMC Cardiovascular Disorders (2009)
12. BMC Clinical Pathology (2009)
13. British Journal of General Practice (2005, 2006, 2008)
14. British Journal of Nutrition (2010)
15. Cell Biochemistry and Biophysics (2011)
16. Clinical Biochemistry (2009)
17. Clinical and Experimental Medicine (2007)
18. Clinical Chemistry and Laboratory Medicine (2007, 2008, 2010)
19. Clinica Chimica Acta (2006)
20. Clinical Endocrinology (2006, 2011, 2012)
21. Clinical Lipidology (2010, 2011, 2012)
22. Current Pharmaceutical Design (2009, 2011, 2012)
23. Diabetes Care (2012, 2013)
24. Diabetes Research and Clinical Practice (2010, 2011, 2013)
25. Diabetology & Metabolic Syndrome (2013)
26. Disease Markers (2009)
27. European Journal of Clinical Investigation (2007, 2008, 2012)
28. European Journal of Internal Medicine (2011, 2012, 2013)
29. European Journal of Obstetrics & Gynecology and Reproductive Biology (2009, 2010)
30. Experimental and Molecular Pathology (2013)

31. Expert Opinion on Drug Safety (2008, 2010)
32. Expert Opinion on Emerging Drugs (2010)
33. Expert Opinion on Investigational Drugs (2010)
34. Expert Opinion On Pharmacotherapy (2010, 2011, 2012, 2013)
35. Heart and Vessels (2011)
36. Drugs (2011)
37. Inflammation Research (2012)
38. International Journal of Cardiology (2009)
39. International Journal of Clinical Practice (2010, 2011, 2012, 2013)
40. Journal of Atherosclerosis and Thrombosis (2010, 2011)
41. Journal of Diabetes and Its Complications (2010)
42. Journal of Obstetrics and Gynaecology Research (2008, 2013)
43. Journal of Rheumatology (2012)
44. Journal of Women's Health (2008)
45. Lipids (2009)
46. Lipids in Health and Disease (2011)
47. Mediators of Inflammation (2012)
48. Metabolism (2009, 2010, 2012)
49. Medical Principles and Practice (2009, 2010)
50. Mini-Reviews in Medicinal Chemistry (2012)
51. Molecular Genetics and Metabolism (2011)
52. Nutrition and Metabolism (2012)
53. Oral Diseases (2013)
54. Plos One (2012, 2013)
55. Progress in Lipid Research (2012)
56. Regulatory Peptides (2011)
57. Regulatory Toxicology and Pharmacology (2011)
58. Scandinavian Cardiovascular Journal (2012)
59. Southern Medical Journal (2006, 2008)
60. Stroke (2007)
61. Swiss Medical Weekly (2008)
62. Translational Research – The Journal of Laboratory and Clinical Medicine (2007)

ATTIVITA' DI REVIEWER PER ALTRE RIVISTE SCIENTIFICHE INTERNAZIONALI (senza Impact Factor)

1. American Journal of Cardiovascular Drugs (2010)
2. Anatolian Journal of Cardiology (2007)
3. Asia-Pacific Journal of Cardiology (2009)
4. Biochemia Medica (2010)
5. Cardiovascular & Hematological Disorders - Drug Targets (2011)
6. Cardiovascular Diabetology (2010)
7. Clinical Medicine Insights: Endocrinology and Diabetes (2010, 2011, 2012)
8. Clinical Medicine: Therapeutics (2009)
9. Expert Review of Cardiovascular Therapy (2009)
10. Journal of the American Society of Hypertension (2010, 2011)
11. Journal of Diabetes and Metabolism (2011)
12. Journal of Diabetology (2011, 2012)
13. Lipid Insights (2010, 2013)
14. Pharmacogenomics and Personalized Medicine (2008)
15. Physiological Research (2012)
16. Recent Patents on Cardiovascular Drug Discovery (2007, 2008)
17. Recent Patents On CNS Drug Discovery (2010)
18. Saudi Medical Journal (2012)
19. The Open Atherosclerosis & Thrombosis Journal (2011)
20. Thomson Reuters' Key Opinions (2010)
21. Vascular Health and Risk Management (2007, 2008, 2009)
22. World Journal of Cardiology (2010, 2011)
23. World Journal of Diabetes (2011)

ATTIVITA' DI REVIEWER PER PROGETTI DI RICERCA NAZIONALI E INTERNAZIONALI

1. Raine Medical Research Foundation, The University of Western Australia, Australia (2008)

2. Dutch Arthritis Association, Germany (2010)
3. Ministry for Science and Technological Development, Republic of Serbia, Serbia (2010)
4. Agence Nationale de la Recherche, France (2010, 2011, 2013)
5. Fundação para a Ciência e Tecnologia, Ministerio da Educacao e Ciencia, Portugal (2012)
6. FIRB – Futuro in Ricerca, Italia (2013)

AMBITI DI RICERCA

Aterosclerosi

Diabete

Dislipidemia

Sindrome Metabolica

Prevenzione Cardiovascolare